The Journal 01/04
Dear Colleagues
Mediterranean Oncology Journal (MOJ) is the oicial journal of the MMOF whose focus is to promote a
multidisciplinary forum facilitating collaboration and exchange of information on current events in diferent
countries of the Mediterranean basin among oncologic disciplines.
MOJ is concerned with the etiology and course of human cancer, cancer treatment and care by publishing
clinical and translational cancer research studies that bridge the laboratory and the clinic contributing to
cancer prevention, early detection, diagnosis, cure, rehabilitation; and diminishing sufering from cancer.
MOJ is happy to announce its 5th issue and looks forward to a broadening of its readership through its
multidisciplinary benefactor MMOF. Together we envisage a bright and productive future. We invite you to
visit our website (www.medmof.org) to review articles and items of interest.
he current issue of MOJ features several article formats that will prove to be of interest to our multidisciplinary
readership. Our editorial board is continuing to develop, attracting interest from once separate ields. We
welcome submissions from all oncology related specialties in a range of formats expressing all aspects of basic,
translational and clinical research.
We sincerely hope and wish to entrust in our readers a desire to collaborate, exchange ideas and report on
activities and research pertaining to all aspects of oncology.
hank you for the interest in our work.
Dimitrios Bafaloukos
Gökhan Demir
Ourania Nicolatou-Galitis
Editors-in-Chief
Samuel Murray
Executive Editor
[email protected]
Mediterranean Oncology Journal (MOJ)
7
The Journal 01/04
Introduction to MOJ
The editorial board has the pleasure to introduce the 5th issue of the Mediterranean Oncology Journal (MOJ), the
official journal of the Mediterranean Multidisciplinary Oncology Forum (MMOF). Through a continuing multidisciplinary
approach, MOJ has been formulated to assist in developing an open-access forum throughout and beyond the
Mediterranean basin. Our editorial board is continuing to develop, attracting interest from once separate fields. We
sincerely hope and wish to entrust in our readers a desire to collaborate, exchange ideas and report on activities and
research pertaining to all aspects of oncology.
he Journal
he Mediterranean Oncology Journal (MOJ) will consider
manuscripts prepared according to the guidelines adopted
by the International Committee of Medical Journal Editors
(‘Uniform requirements for manuscripts submitted to
biomedical journals’, available as a PDF from www.mojmedmof.org). Authors are advised to read these guidelines.
All original research manuscripts submitted to MOJ will be
evaluated by the journal’s Editors. Some manuscripts may be
rejected outright following this evaluation. hose manuscripts
which are judged as being eligible for consideration by the
Editors will be subject to peer-review. MOJ works with a
distinguished team of international experts to ensure the
highest standards of selection and review. All relevant
papers are carefully considered. Once accepted, papers are
published rapidly in print and online.
Submission of an article implies that the work described
has not been published previously (except in the form of
an abstract or as part of a published lecture or academic
thesis), that it is not under consideration for publication
elsewhere, that its publication is approved by all authors
and tacitly or explicitly by the responsible authorities where
the work was carried out, and that, if accepted, it will not be
published elsewhere in the same form, in English or in any
other language, without the written consent of the Publisher.
Manuscripts should be written so that they are intelligible to
the professional reader who is not a specialist in the particular
ield. hey should be written in a clear, concise, direct style.
Where contributions are judged as acceptable for publication
on the basis of scientiic content, the Editor or the Publisher
reserve the right to modify typescripts to eliminate ambiguity
and repetition and improve communication between author
and reader. If extensive alterations are required, the manuscript
will be returned to the author for revision.
prevention, early detection, diagnosis, cure, rehabilitation;
and diminishing sufering from cancer.
MOJ is especially interested in studies and issues that
combine experiences and integration of multiple oncology
related specialties. It is receptive to articles related to human
cancer including, but not limited to: biologic response modiiers
(biomarkers), clinical observations, chemotherapy, clinical
trials, detection, epidemiology, ethical issues, etiology, genetics
and cytogenetics, imaging, immunology and immunotherapy,
oncogenes, pathology and clinicopathologic correlations,
prevention, psychosocial studies, rehabilitation, radiation
therapy, screening, staging, and surgical therapy.
he journal will prioritise clinical trials evaluating new
treatments, accompanied by research on pharmacology and
molecular alterations or biomarkers that predict response
or resistance to treatment, ofer insight into quality of life
and supportive care. Speciic areas of interest include clinical
and translational research in targeted therapies; mechanisms
of drug sensitivity and resistance; pharmacogenetics and
pharmacogenomics; personalized medicine; novel applications
of bioinformatics and biostatistics; immunotherapy and
clinical immunology; gene therapy; radiobiology and radiation
oncology; large scale molecular characterization of human
tumors; diagnostic biomarkers; innovative imaging and
other novel methods with potential applicability to clinical
investigation; clinical genetics; and detection of minimal
disease. MOJ will publish articles that provide the reader
with knowledge and information impacting on the natural
history of malignant disease by providing better care for
patients with cancer.
Scope
Editors-in-Chief
Mediterranean Oncology Journal (MOJ), is the oicial
journal of the MMOF whose focus is to promote a
multidisciplinary forum facilitating collaboration and
exchanging information on what is happening in diferent
countries of the Mediterranean basin among oncologic
disciplines concerned with the etiology and course of
human cancer, cancer treatment and care by publishing
clinical and translational cancer research studies that
bridge the laboratory and the clinic contributing to cancer
Dimitrios Bafaloukos
Gökhan Demir
Ourania Nicolatou-Galitis
9